Clinical behavior of breast cancer in men in a Latin American population
Keywords:
Male breast tumours, Male breast carcinoma, Male breast neoplasmsAbstract
Breast cancer in men is a rare disease in Colombia, with an estimated annual incidence of 1 case per 1,000,000 habitants, which is significantly lower than in other countries.
Objective: To describe the clinical presentation, histopathology, initial treatment and relapse of male patients diagnosed with breast cancer at the National Cancer Institute between 1996 and 2011.
Results: The study population was 27 patients. The main symptoms reported by patients were mass and pain. Most patients (89%) had locally advanced clinical stage (IIIB and IV). NOS ductal histological type was the most prevalent (82%). Hormone receptor was found in 22 of 27 patients, of whom 19 (86%) were positive. The percentage of patients undergoing surgery was 71% (20 patients), and the surgical technique used in 17 of the 20 patients was modified radical mastectomy. Axillary dissection and resection of the CAP was performed on all patients who underwent surgical treatment. The median follow up of patients was 8.9 months. Two patients had systemic relapse. None of the patients had locoregional relapse.
Conclusion: A case series is presented of male patients with breast cancer, which is a disease of low incidence. Our patients are mainly presented in advanced stages, a greater proportion than that described in other Latin American series. Although tumour biology found good prognostic factors, it is not consistent with the fact that most tumours are advanced.
Author Biographies
Javier Angel, Instituto Nacional de Cancerología
Servicio de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Johanna Ibarra, Instituto Nacional de Cancerología
Posgrado de Mastología, Fundación Universitaria de Ciencias de la Salud, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Sandra Diaz, Instituto Nacional de Cancerología
Servicio de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Carlos Lehmann, Instituto Nacional de Cancerología
Servicio de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Mauricio Garcia, Instituto Nacional de Cancerología
Servicio de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Luis Guzman, Instituto Nacional de Cancerología
Servicio de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
David Lopez, Instituto Nacional de Cancerología
Especialista en Epidemiología Clínica, Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
References
Instituto Nacional de Cancerología. Anuario estadístico 2010 [Internet]. Instituto Bogotá D. C.: Nacional de Cancerología; 2012. Disponible en: URL: http://www.cancer.gov.co/∼incancer/instituto//files/libros/archivos/0e6268c58d927ab1199ba15533779dfdAnuario%20Impreso2010.pdf
Mesa G, Matute G, Estrada M, Ocampo A, Restrepo C, Estrada J. Cáncer mamario en hombres. Rev Colomb Cir. 2011;26:293-307.
Martínez-Tlahuel JL, Arce CL, Lara UF. Cáncer de mama en el hombre. Cancerología. 2006;4:201-10.
Proyecto de investigación ACM1. Asociación Colombiana de Mastología. 2014 September 24. Disponible en: URL: http://www.mastologiacolombia.com/userfiles/file/06-03-2013/Presentacion%20Proyecto%20ACM1.pdf
Robledo Abad JF, Caicedo Mallarino JJ, Suárez de Antonio R. Análisis de sobrevida en una cohorte de 1.328 pacientes con carcinoma de seno. Patología. 2005;4:5.
Gradishar W. Male breast cancer. En: Diseases of the breast. Philadelphia: Lippincont Williams & Wilkins; 2009. p. 749-54.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
https://doi.org/10.3322/CA.2007.0010
Siegel R, Ward E, Brawley O, Jemal A. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36.
https://doi.org/10.3322/caac.20121
Ly D, Forman D, Ferlay J, Brinton LA, Cook MB. An international comparison of male and female breast cancer incidence rates. Int J Cancer. 2013;132(8):1918-26.
https://doi.org/10.1002/ijc.27841
Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004;83(1):77-86.
https://doi.org/10.1023/B:BREA.0000010701.08825.2d
Prada N, Angel J, Ríos D. Cáncer de mama en hombres ¿Es una entidad diferente al cáncer de mama en la mujer? Revisión de la literatura. Rev Colomb Cancerol. 2014;18(2): 78-82.
https://doi.org/10.1016/j.rccan.2014.04.003
Rudlowski C. Male breast cancer. Breast Care. 2008;3(3):183-9.
https://doi.org/10.1159/000136825
Kahla PB, Cassaro S, Vladimir FG, Wayne MG, Cammarata A. Bilateral synchronous breast cancer in a male. Mt Sinai J Med. 2005;72(2):120-3.
Rubio Hernández MC, Díaz Prado YI, Pérez SR, Díaz RR, Aleaga ZG. Synchronous bilateral breast cancer in a male. Ecancermedicalscience. 2013:7.
Sun WY, Lee KH, Lee HC, Ryu DH, Park JW, Yun HY, et al. Synchronous bilateral male breast cancer: a case report. J Breast Cancer. 2012;15(2):248-51.
Johansen Taber KA, Morisy LR, Osbahr AJ, Dickinson BD. Male breast cancer: risk factors, diagnosis, and management (Review). Oncol rep. 2010;24(5):1115-20.
Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114-22.
https://doi.org/10.1200/JCO.2009.25.5729
Deb S, Jene N, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC cancer. 2012;12(1):510.
https://doi.org/10.1186/1471-2407-12-510
Vodusek AL, Novakovic S, Stegel V, Jereb B. Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer. Radiol Oncol. 2011;45(4):296-9.
https://doi.org/10.2478/v10019-011-0031-6
Zygogianni AG, Kyrgias G, Gennatas C, Ilknur A, Armonis V, Tolia M, et al. Male breast carcinoma: epidemiology, risk factors and current therapeutic approaches. Asian Pac J Cancer Prev. 2012;13(1):15-9.
https://doi.org/10.7314/APJCP.2012.13.1.015
Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer. 1999;85(3):629-39.
https://doi.org/10.1002/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V
Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51-7.
https://doi.org/10.1002/cncr.20312
Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10(7):471-9.
https://doi.org/10.1634/theoncologist.10-7-471
Teo JY, Tan PH, Yong WS. Male breast cancer in Singapore: 15 years of experience at a single tertiary institution. Ann Acad Med Singapore. 2012;41(6):247-51.
Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, et al. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol. 2012;25(3):398-404.
https://doi.org/10.1038/modpathol.2011.174
Yu XF, Feng WL, Miao LL, Chen B, Yang HJ. The prognostic significance of molecular subtype for male breast cancer: A 10-year retrospective study. Breast. 2013;22(5):824-7.
https://doi.org/10.1016/j.breast.2013.02.005
Nilsson C, Koliadi A, Johansson I, Ahlin C, Thorstenson S, Bergkvist L, et al. High proliferation is associated with inferior outcome in male breast cancer patients. Mod Pathol. 2013;26(1):87-94.
https://doi.org/10.1038/modpathol.2012.145
Nilsson C, Johansson I, Ahlin C, Thorstenson S, Amini RM, Holmq- vist M, et al. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol. 2013;52:102-9.
https://doi.org/10.3109/0284186X.2012.711952
Shak S, Palmer G, Baehner FL, Millward C, Watson D, Sledge GW Jr. Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol. 2009;27(15S):549.
Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104(11):2359-64.
https://doi.org/10.1002/cncr.21526
Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer. 1999;85(3):629-39.
https://doi.org/10.1002/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V
Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987;10(1):55-60.
https://doi.org/10.1097/00000421-198702000-00013
Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer. 1992;65(2):252-4.
https://doi.org/10.1038/bjc.1992.50
Cloyd JM, Hernandez-Boussard T, Wapnir IL. Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009. Ann Surg Oncol. 2013;20(5):1545-50.
https://doi.org/10.1245/s10434-013-2918-5
Cloyd JM, Hernandez-Boussard T, Wapnir IL. Poor compliance with breast cancer treatment guidelines in men undergoing breast-conserving surgery. Breast Cancer Res Treat. 2013;139(1):177-82.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
